Revance to be acquired for $900M+ as Botox trade secrets lawsuit continues
Revance Therapeutics, the maker of Botox competitor Daxxify, will be acquired for more than $900 million. Crown Laboratories will buy out … Sign up to read this article for free. Get free access to a limited number of articles, plus choose …